Cardurion Pharmaceuticals
Cardurion is the first company to successfully develop a CaMKII inhibitor and evaluate it in clinical studies. We are now well positioned to explore multiple cardiovascular diseases, including the rare and fatal genetic disease catecholaminergic polymorphic ventricular tachycardia (CPVT), as well as larger indications including heart failure and atrial fibrillation. PDE9 inhibition presents an opportunity to develop a foundational new treatment for patients with both types of chronic heart failu
Basic Information
- Category: Cardiovascular
- Founded: 2015
- Headquarters: Menlo Park, CA
- Website: cardurion.com
Documented Facts
- Phone: 6178638088 (No linked source recorded for this statement.)
- Email: info@cardurion.com (No linked source recorded for this statement.)
Evidence and Sources
- Cardurion Pharmaceuticals — Official Site (official)
- Cardurion Pharmaceuticals on linkedin (social)
Citation Guidance
Explore Cardiovascular profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Cardurion Pharmaceuticals.
- Canonical profile: https://brandsource.ai/brands/cardurion-pharmaceuticals
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cardurion-pharmaceuticals/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cardurion-pharmaceuticals/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (84/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:09.369Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Cardurion is the first company to successfully develop a CaMKII inhibitor and evaluate it in clinical studies. We are now well positioned to explore multiple cardiovascular diseases, including the rare and fatal genetic disease catecholaminergic polymorphic ventricular tachycardia (CPVT), as well as larger indications including heart failure and atrial fibrillation. PDE9 inhibition presents an opportunity to develop a foundational new treatment for patients with both types of chronic heart failu
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 supporting source linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.